Cargando…

“Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria

BACKGROUND: Nigeria has the second highest number of new HIV infections annually. Therefore, it is important to explore new strategies for preventing new infections. The introduction of pre-exposure prophylaxis (PrEP) for use by persons at high risk of HIV infection has new potential in preventing n...

Descripción completa

Detalles Bibliográficos
Autores principales: Idoko, John, Folayan, Morenike Oluwatoyin, Dadem, Nancin Yusufu, Kolawole, Grace Oluwatosin, Anenih, James, Alhassan, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404045/
https://www.ncbi.nlm.nih.gov/pubmed/25881087
http://dx.doi.org/10.1186/s12889-015-1690-9
_version_ 1782367432750399488
author Idoko, John
Folayan, Morenike Oluwatoyin
Dadem, Nancin Yusufu
Kolawole, Grace Oluwatosin
Anenih, James
Alhassan, Emmanuel
author_facet Idoko, John
Folayan, Morenike Oluwatoyin
Dadem, Nancin Yusufu
Kolawole, Grace Oluwatosin
Anenih, James
Alhassan, Emmanuel
author_sort Idoko, John
collection PubMed
description BACKGROUND: Nigeria has the second highest number of new HIV infections annually. Therefore, it is important to explore new strategies for preventing new infections. The introduction of pre-exposure prophylaxis (PrEP) for use by persons at high risk of HIV infection has new potential in preventing new HIV infections. The aim of this study is to explore the public opinion, community interest, and perceptions about the use and access to PrEP in Nigeria. METHODS: This formative study used a mixed method approach to collect data on public opinions and perceptions on appropriate target groups for PrEP access, community interest, perceptions about the use of PrEP as an HIV-prevention tool, how best to communicate with participants about PrEP, concerns about PrEP use by serodiscordant couples, and suggestions for the design and implementation of a PrEP demonstration project. Telephone and in-depth interviews were conducted, and focus group discussions and consultative meetings were held with critical stakeholders engaged in HIV-prevention, treatment, care, and support programmes in Nigeria. An online survey was also conducted. RESULTS: HIV serodiscordant couples were identified as the appropriate target group for PrEP use. Most respondents felt that PrEP use by key affected populations would help reduce the HIV incidence. Stigma was identified as a major concern and a potential barrier for the acceptance and use of PrEP by HIV serodiscordant couples. Electronic and print media were identified as important means for massive public education to prevent stigma and create awareness about PrEP. In a male dominated society such as Nigeria, HIV-negative male partners in serodiscordant relationships may resist enrolment in PrEP programmes. This may be complicated by the fact that the identified index partner in most serodiscordant relationships in Nigeria is an HIV-positive woman, who is often diagnosed during pregnancy. CONCLUSIONS: PrEP uptake and use by HIV serodiscordant couples in Nigeria may face notable but surmountable challenges. Much depends on the appropriateness of actions taken by multiple players. Motivation of HIV-negative male partners to use PrEP and establishment of effective public education programmes in addressing stigma are essential.
format Online
Article
Text
id pubmed-4404045
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44040452015-04-21 “Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria Idoko, John Folayan, Morenike Oluwatoyin Dadem, Nancin Yusufu Kolawole, Grace Oluwatosin Anenih, James Alhassan, Emmanuel BMC Public Health Research Article BACKGROUND: Nigeria has the second highest number of new HIV infections annually. Therefore, it is important to explore new strategies for preventing new infections. The introduction of pre-exposure prophylaxis (PrEP) for use by persons at high risk of HIV infection has new potential in preventing new HIV infections. The aim of this study is to explore the public opinion, community interest, and perceptions about the use and access to PrEP in Nigeria. METHODS: This formative study used a mixed method approach to collect data on public opinions and perceptions on appropriate target groups for PrEP access, community interest, perceptions about the use of PrEP as an HIV-prevention tool, how best to communicate with participants about PrEP, concerns about PrEP use by serodiscordant couples, and suggestions for the design and implementation of a PrEP demonstration project. Telephone and in-depth interviews were conducted, and focus group discussions and consultative meetings were held with critical stakeholders engaged in HIV-prevention, treatment, care, and support programmes in Nigeria. An online survey was also conducted. RESULTS: HIV serodiscordant couples were identified as the appropriate target group for PrEP use. Most respondents felt that PrEP use by key affected populations would help reduce the HIV incidence. Stigma was identified as a major concern and a potential barrier for the acceptance and use of PrEP by HIV serodiscordant couples. Electronic and print media were identified as important means for massive public education to prevent stigma and create awareness about PrEP. In a male dominated society such as Nigeria, HIV-negative male partners in serodiscordant relationships may resist enrolment in PrEP programmes. This may be complicated by the fact that the identified index partner in most serodiscordant relationships in Nigeria is an HIV-positive woman, who is often diagnosed during pregnancy. CONCLUSIONS: PrEP uptake and use by HIV serodiscordant couples in Nigeria may face notable but surmountable challenges. Much depends on the appropriateness of actions taken by multiple players. Motivation of HIV-negative male partners to use PrEP and establishment of effective public education programmes in addressing stigma are essential. BioMed Central 2015-04-10 /pmc/articles/PMC4404045/ /pubmed/25881087 http://dx.doi.org/10.1186/s12889-015-1690-9 Text en © Idoko et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Idoko, John
Folayan, Morenike Oluwatoyin
Dadem, Nancin Yusufu
Kolawole, Grace Oluwatosin
Anenih, James
Alhassan, Emmanuel
“Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria
title “Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria
title_full “Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria
title_fullStr “Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria
title_full_unstemmed “Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria
title_short “Why should I take drugs for your infection?”: outcomes of formative research on the use of HIV pre-exposure prophylaxis in Nigeria
title_sort “why should i take drugs for your infection?”: outcomes of formative research on the use of hiv pre-exposure prophylaxis in nigeria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404045/
https://www.ncbi.nlm.nih.gov/pubmed/25881087
http://dx.doi.org/10.1186/s12889-015-1690-9
work_keys_str_mv AT idokojohn whyshoulditakedrugsforyourinfectionoutcomesofformativeresearchontheuseofhivpreexposureprophylaxisinnigeria
AT folayanmorenikeoluwatoyin whyshoulditakedrugsforyourinfectionoutcomesofformativeresearchontheuseofhivpreexposureprophylaxisinnigeria
AT dademnancinyusufu whyshoulditakedrugsforyourinfectionoutcomesofformativeresearchontheuseofhivpreexposureprophylaxisinnigeria
AT kolawolegraceoluwatosin whyshoulditakedrugsforyourinfectionoutcomesofformativeresearchontheuseofhivpreexposureprophylaxisinnigeria
AT anenihjames whyshoulditakedrugsforyourinfectionoutcomesofformativeresearchontheuseofhivpreexposureprophylaxisinnigeria
AT alhassanemmanuel whyshoulditakedrugsforyourinfectionoutcomesofformativeresearchontheuseofhivpreexposureprophylaxisinnigeria